Combination of eltanexor and venetoclax eliminates leukemia cells in an MV-4-11 AML xenograft model. An MV-4-11 model was used to test the in vivo effects of eltanexor (ELTA), venetoclax (VEN), and their combination (ELTA/VEN) treatment compared with vehicle. (A) Percentage of human CD45⁺ (hCD45⁺) cells in the peripheral blood (PB) from day 7 to day 28 posttransplantation. **P < .01 and ***P < .001, compared with vehicle at day 28. (B) Percentage of hCD45⁺ cells in the bone marrow (BM) and spleen (SPL) tissues at day 28 posttransplantation. (C) Hematoxylin and eosin staining of bone marrow and spleen from the mice in panels A and B treated with vehicle, eltanexor, venetoclax, or eltanexor-venetoclax combined. Scale bar, 50 µm. Histology images were acquired with an Aperio AT Turbo scanner at an original magnification of ×40; inset box, original magnification, ×100. The data represent the mean of 5 mice per cohort ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001.